Home / Resources / Meet the Organix Director, Mario Gonzalez

Published: 16.12.2024

Meet the Organix Director, Mario Gonzalez

We are pleased to share a conversation with Dr. Mario Gonzalez, a Director at Organix, as he reflects on his journey from Argentina to Massachusetts and provides valuable career insights in celebration of his 30 years with the company.

How did you end up working as a chemist in the USA? I was born and raised in Mar del Plata, Argentina, a popular coastal tourist city. From a young age, I developed a strong interest in science and mathematics, inspired by my uncle, a chemistry professor. This led me to pursue both a bachelor’s and a PhD in chemistry at the University of Buenos Aires. My doctoral research focused on glucocorticoids, requiring a multidisciplinary approach involving synthetic chemistry, spectroscopy, biochemistry, and pharmacology.

Eager to broaden my experience, I accepted a postdoctoral position at Texas A&M University under the mentorship of Professor A. Ian Scott. There, I delved into the synthesis of porphyrins and the biosynthesis of vitamin B12. After nine years of dedicated work and navigating immigration and citizenship processes, I secured a position at Organix in Massachusetts, starting my journey with the company on April 1, 1994.

What is your role at Organix and how have things changed over the years?

As Director and Manager of Analytical Services at Organix, I’ve witnessed significant growth within the company. When I first joined, there were only around 12 employees, and I was tasked with overseeing the analytical equipment due to my expertise in NMR spectroscopy. We started with a modest 80 MHz NMR spectrometer, and over time, we expanded our capabilities by acquiring a 300 MHz instrument and other analytical tools.

This growth allowed us to diversify our services, transitioning from an exclusive focus on synthetic chemistry projects to providing more analytical support for our clients. The 300 MHz NMR spectrometer served us for over 20 years and became almost like a member of the family. Recently, we retired it and upgraded to a 400 MHz instrument, continuing to advance our analytical services and meeting the increasing demands of our clients.

Can you tell us what you like about working at Organix?

Organix has always prioritized employee wellbeing, fostering a friendly and supportive work environment. I greatly appreciate the company’s rigorous scientific approach to projects, which often span diverse topics such as lipids or small molecules. This variety keeps the work both interesting and challenging.

One aspect I particularly enjoy is solving the puzzle of chemical structure elucidation using NMR techniques. A memorable project involved performing the low-yield synthesis of an API described in a client’s patent. We determined that the structure indicated in the patent was incorrect, and our team successfully proposed a mechanism for the actual product, developing a more efficient synthetic route.

Another unique project involved analyzing extracts from a heavily trafficked carpet for a client designing a new vacuum cleaner. We identified typical NMR signals indicating the presence of fats and sugars.

The combination of intellectual challenges and a positive work culture has been a major factor in my 30-year tenure at the company, and I still enjoy coming to work every day.

Can you tell us about your personal life?

I met my wife in Argentina 43 years ago, and together we’ve raised three children, who have blessed us with three adorable grandchildren and two “granddogs.” When I’m not cheering on Argentina during soccer matches, I enjoy the outdoors, from hiking in New England’s stunning forests and mountains to kayaking and biking around the city. Playing disc golf with my son has also become a favorite pastime. Traveling with my family is also a passion of mine, and we have recently vacationed in Canada, Spain, and Argentina.

Resources we think you'll love

CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment

Part 3: Could Regulatory Misalignment Be Delaying Your Submission? A CDMO can have the best scientists, excellent facilities, and strong technical execution, yet still fall short when it comes to regulatory alignment. This disconnect between scientific performance and regulatory readiness is one of the most damaging red flags in drug development as it could delay […]
View article

Whitepaper

5 CDMO red flags you can’t ignore: A guide for biotechs and pharma

Selecting the right CDMO is one of the most important choices a biotech or pharma team will make. The right partner helps you move efficiently toward IND or IMPD, safeguard quality, and anticipate regulatory needs before they become roadblocks. The wrong one can mean delays, rising costs, and lost momentum. At Exemplify BioPharma, a Symeres company, […]
View article

Whitepaper

CDMO red flags you can’t ignore: Underestimating technology transfer complexity

Part 2: Why “Scale-Up” Isn’t Just a Bigger Batch Transitioning a process from discovery scale to GMP manufacturing is almost never straightforward. What runs smoothly at 100 milligrams in the lab can behave very differently at the kilogram scale. Yet too many programs falter because the complexity of this transition is underestimated or treated as […]
View article

Blog

O.N.E Symeres: A practical approach to real-world drug development

No drug development program runs perfectly. Chemistry misbehaves, funding shifts, and timelines tighten. But what defines a reliable partner is how they respond. O.N.E Symeres is the framework we use to keep projects moving through uncertainty: openness, nimbleness, and expertise.
View article

Whitepaper

CDMO red flags you can’t ignore: Undefined or shifting project scope

Part 1: Is an Undefined Scope Putting Your Project at Risk? Selecting the right CDMO is one of the most important decisions in drug development. Yet even experienced biotechs and pharma companies can find themselves trapped in projects where the initial excitement gives way to frustration, and one of the most common culprits is a […]
View article

Whitepaper

Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry

By combining automation, data-driven design, and deep synthetic expertise, Symeres is redefining how chemists generate and optimize compound libraries, bringing speed, scalability, and creativity to modern drug discovery.
View article

Webinar | On-demand

From racemic to pure the art and science of enantiomer separation

From the classical and Dutch resolution methods to preferential crystallization and deracemization, learn the best ways to obtain your desired purity!
View article

Whitepaper

IND & IMPD enabling developability roadmap

Drug discovery and development is a complex and iterative process that involves the identification, design, development, testing, and approval of new pharmaceutical drugs for use in patients. It encompasses a series of scientific, regulatory, and commercial activities aimed at discovering and bringing safe and effective medicines to the market. A key milestone in this process […]
View article

Whitepaper

Innovations in unnatural amino acids: Advancing functional diversity and applications

Unnatural amino acids enable groundbreaking advancements in drug discovery, biomaterials, and peptide design by introducing novel chemical functionalities that enhance stability, specificity, and bioactivity. This whitepaper highlights Symeres’ expertise in synthesizing unnatural amino acids, including side-chain modifications, N-functionalization, and cyclic variants, for applications in pharmaceuticals, diagnostics, and materials science. Utilizing advanced techniques like biocatalysis and […]
View article

Whitepaper

Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D

Our experience in overcoming scaleup challenges and harnessing the benefits of non-noble-metal catalysis makes Symeres the CRO of choice for challenging steps, such as the Ullmann reaction.
View article

Whitepaper

Managing nitrosamines in the pharmaceutical industry: A comprehensive approach

A comprehensive overview of nitrosamine risk assessment, including potential formation, scavenging, and analysis, is described here.
View article

Whitepaper

Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction

Here at Symeres, we have our new ‘Solid-State Center of Excellence’, and in this whitepaper we describe how we utilize our expertise and novel innovation to further our solid-state capabilities.
View article

Whitepaper

Stable isotope-labeled compounds

Discover how Symeres applies advanced synthetic chemistry and ADME expertise to design, produce, and study stable isotope-labelled compounds that enhance precision in drug development.
View article

Whitepaper

Unlocking the potential of high-throughput screening: Symegold library design and expansion insights

Learn how Symeres combines advanced chemistry platforms and deep discovery expertise to design and expand the SymeGold library, driving more efficient high-throughput screening and smarter hit identification.
View article

Interviews

Insights into drug discovery and development 2025

Here we interview our Director of Medicinal Chemistry, Anita Wegert, for her insights into drug discovery and development for 2025. This interview was conducted an interviewer from the Drug Discovery and Development Europe event and we were able to share our expertise. Curious how our insights can help your next project?
View article

Interviews

Interview with the computer-aided drug design (CADD) department

Our Computer Aided Drug Design department supports our clients' drug discovery projects with some of the best (predictive) software.
View article

Interviews

Interview with the new Managing Director of Symeres Groningen

On October 2, Dr Melloney Dröge started in her new role as Managing Director for the Groningen site.
View article

Interviews

An interview with Yadan Chen and Paul O’Shea

We are pleased to introduce the founders of Symeres’ daughter company Exemplify in New Jersey: Yadan Chen, CEO, and Paul O’Shea, Chief Scientific Officer. Who are they? What do they stand for? And how does Exemplify fit with Symeres?
View article

Interviews

An interview with Anu Mahadevan and Paul Blundell

We proudly introduce the founders of Symeres’ daughter company Organix in Boston: Anu Mahadevan, CEO, and Paul Blundell, President at Organix. Who are they? What do they stand for? And how does Organix fit with Symeres?
View article

Blog

Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same

Organix, a Symeres company, developed scale up conditions of the synthesis of 25-hydroxy cholesterol 3-monosulfate (sodium salt) from cholesterol. After the protection of the hydroxy group (acetate) and double bond (debromination), the hydroxy group in position 25 was introduced using oxone and trifluoromethylethylketone. Then the 3-hydroxy group and double bond were deprotected, and the resulting […]
View article

Webinar | On-demand

In vivo pharmacokinetic experiments in preclinical drug development

Despite a good part of ADME research in drug discovery and preclinical development can be performed using various in silico or in vitro systems, eventually it becomes necessary to evaluate the pharmacokinetic (PK) profile in animals to elucidate in vivo DMPK properties of the drug candidates.
View article

Webinar | On-demand

Accelerating medicinal chemistry by rapid analoging

Medicinal chemistry is the art of rapidly evolving initial hits to clinical candidates via smart, information driven multiparametric optimization.
View article

Webinar | On-demand

Solid-state chemistry part II: Optimal form selection by controlled crystallization

The webinar by Dr. Edwin Aret of Symeres focuses on advanced strategies for selecting and controlling solid forms of pharmaceutical compounds through crystallization techniques.
View article

Webinar | On-demand

Route scouting for kilogram-scale manufacturing of APIs

The webinar by Dr. Martin Strack provides an in-depth exploration of the strategies and considerations involved in developing scalable synthetic routes for Active Pharmaceutical Ingredients (APIs)
View article

Webinar | On-demand

Solid-state chemistry part I: Introduction

This webinar, presented by solid-state expert Edwin Aret, offers an insightful introduction to the field of solid-state chemistry.
View article

Speak with our experts

Let’s discuss how Symeres can support the discovery and development of your next breakthrough